Abstract
Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Current Stem Cell Research & Therapy
Title:Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Volume: 8 Issue: 4
Author(s): Nadir Askenasy
Affiliation:
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Abstract: Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Export Options
About this article
Cite this article as:
Askenasy Nadir, Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes, Current Stem Cell Research & Therapy 2013; 8 (4) . https://dx.doi.org/10.2174/1574888X113089990001
DOI https://dx.doi.org/10.2174/1574888X113089990001 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Point-of-Care Testing in Diabetes Care
Mini-Reviews in Medicinal Chemistry Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Current Medicinal Chemistry Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature
Current Clinical Pharmacology Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Editorial [Hot Topic:Continuous Glucose Monitoring Systems: Toys or Tools (Guest Editor: Christophe De Block)]
Current Diabetes Reviews Current Issues in Intravenous Fluid Use in Hospitalized Children
Reviews on Recent Clinical Trials Local Cerebral Blood Flow is Preserved in Sepsis
Current Neurovascular Research Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews